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 21 
 22 
ABSTRACT 23 
Purpose: Infective Endocarditis (IE) incidence remains high with considerable fatality rates; guidelines for 24 
prophylaxis against IE are currently under review in some settings which highlights the importance of main-25 
taining up-to-date epidemiological estimates about the most common microbial causes. The objective of this 26 
systematic review, following PRISMA guidelines, was to identify the most common microbial causes of IE 27 
in recent years.  28 
Methods: Medline was searched from January 1, 2003 to March 31, 2013 for all articles containing the term 29 
“infective endocarditis”. All relevant studies reporting diagnostic results were included. Special patient sub-30 
populations were assessed separately.  31 
Results: 105 studies were included, from 36 countries, availing data on a total of 33,214 cases. Staphylo-32 
coccus aureus was found to be the most common microorganism, being the most frequent in 54.3% of stud-33 
ies (N=57) (and in 55.4% of studies using Duke’s criteria for diagnosis (N=51)). Viridans group streptococci 34 
(VGS), coagulase-negative staphylococci (CoNS), Enterococcus spp and Streptococcus bovis were among 35 
the most common causes. S. aureus was the most common pathogen in almost all population subgroups, 36 
however, this was not the case in patients with implantable devices, prosthetic valves, or immunocompro-37 
mised non-HIV, as well as in the sub-group from Asia, emphasizing that a global one-size-fits-all approach 38 
to the management of suspected IE is not appropriate.  39 
Conclusions: This review provides an evidence-based map of the most common causative agents of IE, 40 
highlighting S. aureus as the leading cause in the 21st century. The changing epidemiology of IE in some 41 
patient sub-groups in the last decade and the very high number of microbiologically undiagnosed cases 42 
(26.6%) suggest the need to revisit IE prophylaxis and diagnostic strategies. 43 
  44 
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 45 
1. Introduction 46 
 47 
Infective endocarditis (IE) remains one of the most serious conditions in medicine in the 21st century [1,2]. 48 
The introduction of antibiotics in its treatment has decreased the mortality rates of the disease, however 49 
these can reach up to 20% in hospital and can be even higher on 1-year follow up (up to 40%) [3]. Fatality 50 
rates of IE remain high and 2.7%of patients suffer an unexpected sudden death at 6 months during or after 51 
treatment [4]. After the near eradication of rheumatic fever in the western world, infective endocarditis ac-52 
counts for the vast majority of cases of endocarditis with an incidence ranging between 1.7 and 11.2 cases 53 
per 100.000 people/year [5]. Overall, the male to female ratio is estimated at around 2 but outcomes tend to 54 
be worse in women [6]. 55 
 56 
Incidence of IE is higher in elderly patients (reaching 14.5 cases per 100.000 person/years) [7] as well as 57 
among specific sub-populations such as injectable drug user(s) (IDUs), [8] where clinical characteristics of 58 
the disease also differ from the general population. [8] Diabetes mellitus, invasive techniques, haemodialy-59 
sis [6,10] and implantable cardiac devices [11] have caused a shift in the most commonly identified infective 60 
microorganisms in the past decades significantly increasing the prevalence of staphylococcal infections [12] 61 
which generally had shown higher mortality rates when compared to streptococcal infections.[6,10,13] As a 62 
result, many studies have emphasized the need to better understand the mechanism of infection in cardiac 63 
devices and reinforce preventive measures of health-care associated staphylococcal bacteraemia in an ef-64 
fort to decrease IE incidence. [11,13] 65 
 66 
Limited understanding of the disease pathogenesis and progression is reflected upon different guidelines 67 
for prophylaxis among countries in recent years.[14]  Identifying the most common microbial agents in IE is 68 
of particular current interest, following publication of new research at the American Heart Association meet-69 
ing in Chicago in November 2014 showing increase in the incidence of infective endocarditis and the sub-70 
sequent launch of a review of the guidance on Prophylaxis for Infective Endocarditis by the National Insti-71 
tute for Health and Care Excellence, in the UK (http://www.nice.org.uk/news/press-and-media/nice-to-72 
review-its-guidance-on-the-use-of-antibiotics-to-prevent-infective-endocarditis). As far as treatment is con-73 
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cerned, IE remains a therapeutic challenge to date primarily due to the changing epidemiology of the caus-74 
ative pathogens together with the lack of knowledge on the exact mechanism of the disease and the insuf-75 
ficiency of diagnostic and therapeutic methods.[1] Early surgical therapy is increasingly becoming more 76 
popular with studies showing superior outcomes when compared to conventional treatment.[15]  77 
 78 
In this context, the objective of this study was to systematically review the literature to identify and prioritize 79 
the most common microbial factors causing IE in recent years and provide insight on special subpopula-80 
tions. The rationale was that if more definitive conclusions on microbial associations could be drawn, these 81 
could inform prevention and treatment strategies. In this context, the study followed an inclusive approach 82 
to record study results predicting the most common microbial diagnosis for the patients presenting with IE. 83 
 84 
2. Methods 85 
2.1. Search strategy 86 
This systematic review adopted  the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 87 
(PRISMA) guidelines.[16]  Eligible articles were identified by a systematic search of Pubmed bibliograph-88 
ical database for studies published from January 1, 2003 to March 31, 2013 by three investigators (CV, NV, 89 
LP) working independently. All articles derived from a search with the term “infective endocarditis” were 90 
assessed. In addition, all references of eligible articles retrieved by the search were scanned. Whenever full 91 
text was not available or additional data information was required, an e-mail was sent to the corresponding 92 
authors. 93 
Study eligibility was based on the following inclusion criteria: (1) observational studies in patients with in-94 
fective endocarditis and explicit mention of the pathogens related to the disease, (2) more than five patients 95 
with infective endocarditis reported in the article. Discrepancies were discussed until complete agreement 96 
was reached; an additional reviewer (AK) gave input where required to reach consensus. The selection pro-97 
cess excluded: (1) reviews and secondary research, (2) case reports, (3) missing full text or key data, also 98 
excluding articles that only commented on a single pathogen, (4) overlapping populations, (5) irrelevant ar-99 
ticles, ie articles not reporting on the etiologic agents of IE(6) articles published in languages other than 100 
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English. In the interest of not excluding clinically important case series, no formal quality assessment of eli-101 
gible articles was undertaken. 102 
2.2. Data extraction 103 
The following variables were extracted and tabulated for each eligible study: first author’s name, year of 104 
publication, study design, country of origin, study site, patients’ age (mean, standard deviation, median, and 105 
age range or InterQuartile Range if available), reported use of Duke’s diagnostic criteria, number of cases, 106 
number of unidentified microbes, numbers of cases reported per microbe, as well as special patient subpopu-107 
lations. Due to the anticipated high heterogeneity of the included studies and the inclusive character of the 108 
search strategy, the five most frequent microbes associated with each study were recorded (with polymicro-109 
bial and unspecified cases included when being numerically among the five main causes) and sensitivity 110 
analyses were performed. A purely descriptive approach was adopted (i.e. data expressed as non-weighted 111 
means whenever possible) concerning continuous variables. Microbial causes results and all descriptive var-112 
iables were treated in numerical values of totals or means. No further statistical analysis was undertaken. 113 
The species was recorded where available, otherwise the genus was used.  114 
 115 
3. Results 116 
3.1. Eligible articles 117 
The initial search of the Pubmed database yielded 3,397 potentially relevant articles, 2,313 of which were 118 
excluded as irrelevant and 477 as not written in English. For the remaining 607 articles, the full-text was 119 
studied. Further exclusion reasons comprised 345 case reports, and 107 secondary research papers. Fourteen 120 
were excluded on account of overlapping populations (by majority relating to the International Collaboration 121 
on Endocarditis Prospective Cohort Study), results from 23 studies could not be included because they only 122 
described one pathogen, while for 13 studies, though requested through repeat correspondence, data could 123 
not be retrieved, in part, because there was no response from the corresponding authors. Four authors pro-124 
vided additional data on their studies [17–20]. 125 
Eventually, 105 studies were included in this review (Figure 1) availing data for a total of 33,214 cases of 126 
infective endocarditis. Although the mean age of patients was not available in all studies, virtually all age 127 
groups were represented, with age ranging from 6 days to 100 years. However, paediatric patients were un-128 
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der-represented compared to adults. Ninety-two studies (87.6%) used the Duke’s criteria or modified Duke’s 129 
criteria for case selection. 130 
As shown in Table 1, the majority of included studies (92.4%, N=97) used a cohort design (prospective: 30 / 131 
retrospective: 67), and only 5 were cross-sectional (4.8%) and 3 case-control (2.9%). 132 
3.2. Most common microorganisms 133 
Overall Staphylococcus aureus was found to be the most common microorganism causing infective endo-134 
carditis being isolated as one of the five most common microorganisms in 99 out of 105 studies (94.3%), 135 
and being the most frequent in more than half of the studies (N=57, 54.3%), and second in a further third of 136 
the studies (N=32, 30.5%). 35 of the above-mentioned 99 studies report data regarding MRSA strains; 137 
MRSA was isolated in the 4.5% to 51.1% of S. aureus infective endocarditis cases, while the median per-138 
centage was 28.1 Viridans group streptococci (VGS) were the second most commonly reported microorgan-139 
isms, being the primary cause in over a fifth (21.9%) of all studies (N=23), and second in 24 studies (22.9%) 140 
or third in 10. Coagulase-negative staphylococci (CoNS) were the most common not otherwise specified 141 
group recorded, isolated as the most frequent cause in 8.6% of studies (N=9), and reported as one of the five 142 
most common in 73.3% (N=77) of studies. Enterococcus spp was only rarely the most common microbe re-143 
ported (N=3), but it appeared consistently among the 5 most frequent in the majority of all studies (78.1%, 144 
N=82). Cases of Streptococcus bovis were also frequently reported, being the most common cause in 3 stud-145 
ies. The top decile of our studies (N=11) comprised 18,065 cases. Of these studies, when using Duke's crite-146 
ria, all but one had S. aureus as the most commonly diagnosed microbe. Only Day et al included a special 147 
sub-group: pediatric patients. This study contributes 61.6% of the sample of this sub-group, substantially 148 
shifting the most common result towards S. aureus, as 4/7 studies report other microbes as most common. 149 
However, absolute sum of the results still points towards S. aureus, accounting for 45.4% of all cases. 150 
Table 2 summarises the most common pathogens per population category. 151 
 152 
3.3. Special populations 153 
Congenital heart defects: Five cohort studies (2 from Asia, 3 from Europe) examined 672 patients with con-154 
genital heart defects. S. aureus and VGS were almost equally identified among the most common pathogens 155 
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in all five studies. Alpha hemolytic streptococci [21] and S. bovis [22] were also reported. All patients were 156 
included irrespective of the type of their congenital heart disease and whether they had undergone surgical 157 
correction or not. Patients were not stratified by age and effect of surgery 158 
Prosthetic valve: Three cohort studies reported exclusively 994 patients with prosthetic valve endocarditis. 159 
CoNS were the most commonly isolated microorganisms being the primary cause in one study and among 160 
the three most common microorganisms in the other two studies. S. aureus was the primary cause in one 161 
study and among the four most common pathogens in the other two studies. VGS were the main pathogen in 162 
the study authored by Lalani et al [23] Enterococcus spp. was the 3rd most common microorganism in two 163 
out of three studies. Finally, Propionibacterium acnes appeared as the second most common causative agent 164 
in one study but not among the 5 most common microorganisms in the other two studies [24]. 165 
Paediatric patients: Seven retrospective cohort studies (3 from N. America, 3 from Asia and 1 from Oceania) 166 
referred to 1,026 paediatric patients, their age ranging from 3 days to 20 years. S. aureus was again found to 167 
be the most commonly isolated microorganism responsible for the disease (1st in 3 studies and 2nd in 4), fol-168 
lowed by VGS (1st in 3 studies and 2nd in 2). CoNS ranked as the 3rd most common pathogen in 5 out of 7 169 
studies. Two studies found Candida albicans to be the 2nd and 3rd most common pathogen respective-170 
ly,[25,26] while cases of Enterococcus spp were also reported. 171 
Injectable drug user(s) (IDUs): Four retrospective cohort studies (N. America: 2, Asia: 1, Europe: 1) com-172 
prising a total of 580 cases examined the characteristics of IE among populations of IDUs. As expected, S. 173 
aureus was by far the most commonly isolated microorganism (1st in 4 out of 5 studies). Three studies report 174 
MRSA strains, which were isolated in 11.4%, 45.2%, and 46.4% of S. aureus infective endocarditis cases, 175 
respectively VGS followed (2nd in 2 studies and 3rd in 1 more study) and CoNS completed the triad of the 176 
most commonly isolated microorganisms (3rd in 2 studies). Enterococcus spp (4th in 2 studies) and C. albi-177 
cans (2nd and 5th in 2 studies respectively) were also reported. 178 
Implantable heart devices: Six cohort studies examined 505 cases in patients with implantable heart devices. 179 
S. aureus and CoNS were isolated with equal frequency as the primary causative agents of the disease and 180 
were consistently found in the top 5 microorganisms causing IE in this special population. Enterococcus spp 181 
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and Gram-negative bacteria, though not usually found among the 3 most common pathogens, comprised a 182 
big number of cases accounting as the 4th or 5th most common microbial agent isolated. 183 
Fungal Endocarditis: Sixteen studies (2,145 cases), fifteen cohort and one cross-sectional, reported fungi as 184 
one of the five most frequent microbes causing infective endocarditis. These studies came primarily from 185 
Europe (N=9) and Asia (N=5), with 1 additional in USA and 1 in Latin America. Fungi were reported as the 186 
third cause in one study, fourth in 2 studies and fifth in 2 studies. Candida species are reported in two studies 187 
as the fourth most common cause of endocarditis. C. albicans was the most frequently isolated fungus, as it 188 
is found in 6% of studies (N=7), thrice as the second cause, twice as the third and once as the fourth and 189 
fifth cause. Finally, Aspergillus fumigatus and Candida parapsilosis were isolated in only one study. 190 
Using Duke’s criteria: A sensitivity analysis was performed among the 92 studies reporting use of the 191 
Duke’s criteria for diagnosis of IE and accounting for 22,081 cases of IE. The five most common pathogens 192 
were, in order of decreasing frequence, S.aureus, VGS, CoNS, Enterococcus spp and Streptococcus spp. 193 
S.aureus was found in a total of 5,546 cases and was the most common pathogen in 51 of these studies and 194 
second in 29. VGS were the second most common cause, found in a total of 2,694 cases, and it was the first 195 
cause in 24 studies and second in 22. CoNS followed, accounting for 1,765 cases of IE in total, being first in 196 
5 studies and second in 9. Enterococcus spp was the fourth most common cause, isolated in 1,543 cases, and 197 
being the second common pathogen in 4 studies. Finally, Streptococcus spp was the fifth leading cause of 198 
IE, isolated in 1,145 patients in total, being the most common cause in 7 studies and second in 6.  199 
3.4. Results per continent 200 
Forty-nine studies (46.7%, N=12,752 patients) originate from European countries, 29 from Asia (27.6%, 201 
N=12,105), 14 from North America (13.3%, N=1,918), 4 from Africa (3.8%, N=602). 4 from Oceania 202 
(3.8%, N=1,681 patients), 2 from South America (1.9%, N=452), and three were multi-continent (2.9%, 203 
N=3,704 patients). Table 3 summarizes the main microbial causes per continent. 204 
4. Discussion 205 
4.1. General population 206 
As presented above, our study concluded that the five most common pathogens causing infective endocardi-207 
tis in the 21st century are by order of frequency: S. aureus, viridans group streptococci (VGS), coagulase-208 
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negative staphylococci (CoNS), Enterococcus spp and, S. bovis. S. aureus was the most common microor-209 
ganism in over half of the studies included in our research. 210 
Our results highlight the change in the epidemiology of the causative agents of IE throughout time, as they 211 
contrast studies from the 1990s reporting streptococcal infections outnumbering staphylococcal [27,28], but 212 
are consistent with more recently published literature: Slipczuk et al report a significant increase in S. aureus 213 
IE which  may associate with increasing numbers of  IDUs in North America.[29] Also, in a review pub-214 
lished in 2006 streptococci and staphylococci were found to account for the vast majority of infective endo-215 
carditis cases.[30] Enterococci have been found to be the third leading cause of IE in other studies as well. 216 
[13,31] On the other hand, quite surprisingly, a recent study carried out across 11 years in France identified 217 
S. bovis to be responsible for 149 of 847 cases (17.6%) [4]. These changes in the pattern of the pathogens of 218 
IE can be attributed to several factors, such as modern cardiology invasive techniques, non-nosocomial 219 
health care acquisition, the growing importance of the central line associated blood stream infections 220 
(CLABSIs), the percentage of colonization by MRSA in cardiac surgery patients, the aging population and 221 
the rise of enterococci and S. bovis. Of note, frequency of identified microbes was not identified in the same 222 
pattern in Asia, strongly emphasizing that a global one-size-fits-all approach to the management of IE pa-223 
tients is not appropriate. 224 
4.2. Special groups 225 
This is the first study that has systematically assessed the cause of IE in several special patient groups of im-226 
portance. Our study found that those with congenital heart defects did not differ significantly compared to 227 
the general IE population as far as causative microorganisms are concerned. S. aureus and VGS were the 228 
most commonly isolated microorganisms. Of interest, patients with bicuspid aortic valve were more prone to 229 
perivalvular abscess formation particularly when S. aureus was the causative microorganism of IE [22] and 230 
surgical intervention was required in a big number of cases- ranging between 26-72% - to treat infective en-231 
docarditis.[21,22,32,33] Taking into consideration that oral hygiene and dental prophylaxis seem to be of 232 
vital importance among these patients[32,34] and that incidence of IE after reparative surgery has been in-233 
creasing [34] revision of the current guidelines regarding patients with CHD is crucial. Similarly, among 234 
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paediatric patients S. aureus was the most common pathogen, followed by VGS, CoNS, C. albicans and En-235 
terococcus spp. This is in accordance with a recent study which reported increasing frequencies of S. aureus, 236 
CoNS and fungal IE among children. [35] A large proportion of the affected children had underlying heart 237 
disease as described in all the included studies. Of interest, Marom et al. noted that children with no predis-238 
posing factors exhibited a more aggressive form of the disease with S. aureus and S. pneumoniae being sig-239 
nificantly more frequent among these patients.[25] On the other hand, patients with prosthetic valves were 240 
found  positive for CoNS in the majority of cases, while S. aureus appeared second and VGS third. Of inter-241 
est, CoNS infection conferred increased risk for perivalvular abscess development and heart failure com-242 
pared to S.aureus and VGS IE. [23] Also, proportion of patients with early death was higher among patients 243 
with CoNS IE.[24] Thus, prompt attention should be given to antimicrobial prophylaxis against CoNS in 244 
patients with prosthetic valves.  Our study identified that S. aureus was the most commonly reported cause 245 
of IE in IDUs and patients with implantable heart devices. Cases of CoNS and fungal endocarditis need to 246 
be explored in these patients. The extensive use of invasive methods and implantable devices in the past 247 
decades has changed the spectrum of microorganisms that tend to colonise the heart valves causing infective 248 
endocarditis. Cabell et al described a 42% increase in the use of implantable heart devices between 1990 and 249 
1999, especially depicting the increased frequency of the use of permanent pacemaker, and leading to a 250 
124% increase in device infections and 50% increase in infective endocarditis prevalence.[11] Thanavaro et 251 
al suggested that the increased mortality and morbidity due to implantable cardiac devices infection can be 252 
partly attributed to the increased age of the patients and comorbidities [36]. Taking this evidence into ac-253 
count, revisions in guidelines regarding chemoprophylaxis after such procedures could be explored. 254 
4.3. Limitations and strengths 255 
Though inclusive, significant heterogeneity and a number of poorly designed studies among the included is 256 
the primary limitation of this review [37]. For example, a large cohort study from Thailand that reported 257 
non-fermentative Gram-negative rods as the leading cause is subject to various limitations, such as lack of 258 
use of the modified Duke’s criteria for patient selection and failure to identify a causative agent in 86.59% 259 
of cases.[38] Also, the included studies used different ways to record the pathogens; some agents are reported by 260 
genuses, others by subgenuses and others by species making presentation of data inconsistent in terms of nomen-261 
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clature. Notably, evidence of MRSA infection was only recorded in 35 out of 99 studies in which S. aureus 262 
was identified as 1 of the 5 most common microorganisms, and evidence of vancomycin-resistant S. epider-263 
midis (VRSE) only in 1 study implicating enterococcal infections. A large number of studies routinely did 264 
not specify the species of fungi or Gram-negative microorganisms. Another possible limitation of this study 265 
is that the world population is represented disproportionally with the cases included in this review, as cases 266 
from Europe and Asia represent a 74.28% of the total cases displayed. Also, excluding case reports and case 267 
series may lead to negative reporting bias for emerging pathogens and excluding non English literature may 268 
lead to selection bias. 269 
Finally, in one in four of our included cases (8,835/33,214, 26.6%) the causative agent was not identified. 270 
The above most likely reflect resource limited settings (or in a few cases poor laboratory techniques) and 271 
highlight the importance of the use of newer techniques, such as PCR, which may lead to increase in the de-272 
tection of the etiologic agents of infective endocarditis.  273 
The review benefits from its strict methodology and the large number of studies and cases analysed. Sensi-274 
tivity analyses were performed throughout. Notably, all five continents and various special subgroups are 275 
represented.  276 
5. Conclusion 277 
The current review is the largest epidemiological study regarding causative agents in IE  including a collec-278 
tive cohort of 33,214 infective endocarditis cases. The results document the rapidly changing profile of IE 279 
etiology, especially among special sub-groups of patients, as well as the predominance of S. aureus as the 280 
leading cause for infective endocarditis in the 21st century. However, the most common agent differed 281 
among several special groups of patients (most notably implantable heart devices) as well as patients from 282 
Asia, showing the need to tailor patient prophylaxis and treatment. Also, our study showed that in an im-283 
portant percentage of IE cases the responsible agent remained unidentified, even in high-level reference la-284 
boratories; this stresses how newest techniques have the capacity to change the profile of IE diagnosis and 285 
prevention. The results further emphasize the need to revisit IE prophylaxis and management strategies, as 286 
well as improving the reporting of the causative agents in future studies.. 287 
  288 
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Table 2  291 
Most common microbes in special populations 292 
 293 
Special populations  
[cases] 
Most common microbes  
HIV [N=91] S. aureus / E. faecalis / CoNS /  VGS / Pseudomonas 
spp 
Cardiac resynchronization 
therapy device [N=505] 
S. aureus  CoNS (equal rates) / S. pneumoniae / E. 
faecalis 
Dialysis [N=233] S. aureus / CoNS / E. faecalis / VGS / P. aeruginosa 
Paediatric [N=1026] S. aureus / VGS / CoNS / Enterococcus spp / S. 
pneumoniae  
ICU [N=228] S. aureus / Oral streptococci  / Other Group D strepto-
cocci / Enterococcus spp / Gram (-) bacteria 
Transplantation [N=27] Staphylococcus spp / Polymicrobial / Fungi 
Congenital heart defect 
[N=672] 
VGS / S. aureus  / CoNS / S. bovis / Enterococcus spp 
Prosthetic valve [N=994] CoNS / S. aureus / VGS / Enterococcus spp / S. bovis  
Injectable drug user(s) 
(IDUs) [N=580] 
S. aureus / VGS / CoNS / Enterococcus spp / C. 
albicans 
Cross infection (healthcare 
associated) [N=495] 
S. aureus / E. faecalis / VGS / S. epidermidis / S. bovis  
Diabetic [N=309] S. aureus /Other Group D streptococci / Oral strepto-
cocci /  CoNS / Enterococcus spp 
Critically ill [N=198] S. aureus / Streptococcus spp / Enterococcus spp / 
CoNS / Enterobacter spp 
Epidural abscess [N=6] S. aureus / CoNS / E. faecalis 
Immunocompromised (non 
HIV) [N=56] 
E. faecalis / S. aureus / Streptococcus spp / E. coli / K. 
ozaenae 
 294 
 295 
 296 
CoNS: coagulase-negative staphylococci 297 
  298 
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Table 3 299 
Most common microbes per continent 300 
Continent [cases] Most common microbes 
Europe [N=12,752] S. aureus / VGS/ CoNS / Enterococcus spp / S. 
bovis 
Asia [N=12,105] VGS / Streptococcus spp / S. aureus / Staphy-
lococcus spp 
North America [N=1,918] S. aureus / VGS/ CoNS / Streptococcus spp / 
Enterococcus spp 
Oceania [N=1,681] S. aureus / Streptococcus spp / Enterococcus 
spp / CoNS 
Africa [N=602] S .aureus / Oral streptococci / CoNS / Strepto-
coccus spp 
South America [N=452] S. aureus / Enterococcus spp / CoNS / HACEK 
Multi-continent [N=3,704] S. aureus / VGS/ CoNS / Enterococcus spp / S. 
bovis 
 301 
 302 
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